Shortened 20-Minute Agalsidase Beta Infusions Prove Safe in Fabry Disease Trial
A phase 4 study found that treatment-experienced Fabry disease patients safely tolerated accelerated 20-minute agalsidase beta infusions without infusion-associated reactions.

